Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Armada Acquisition Corp. III (AACI)

Armada III agrees to merge with Brains Bioceutical at $750.0 million valuation

Neutral Impact 5 of 5 m&a Written later

Armada Acquisition Corp. III, a special purpose acquisition company, signed a business combination agreement on October 31, 2026 with Brains Bioceutical Corp., a Vancouver-based maker of cannabinoid active pharmaceutical ingredients and drug developer. The deal values Brains at an implied pre-money equity value of approximately $750.0 million, and the combined company is expected to trade on Nasdaq as BAPI, with closing expected in the second quarter of 2027 subject to shareholder and regulatory approvals.

Key points

  • Enterprise value of $750.0 million, with new PubCo shares priced at a $10.20 reference value per share
  • 14,705,882 additional earnout shares held in escrow, released if PubCo shares reach $12.50 or $15.00 volume-weighted average price over a three-year earnout period
  • Closing expected in the second quarter of 2027, subject to shareholder votes, Form F-4 registration effectiveness, Nasdaq listing approval and regulatory approvals
  • Combined company expected to be named Brains Therapeutics Corp. and trade on Nasdaq under the ticker BAPI

The filing

CompanyArmada Acquisition Corp. III (AACI)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:05 PM ET
Accession number0001193125-26-449772

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.